Stay updated with breaking news from Drug Developer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Diana Hausman, M.D., Accomplished Oncologist and Drug Developer, Appointed Chief Medical Officer Kyle Rasbach, Ph.D., Pharm.D., Experienced Biotechnology Portfolio Manager, Appointed Chief Business...
ZURICH (Reuters) -Roche agreed to take over obesity drug developer Carmot Therapeutics for $2.7 billion, joining a list global contestants seeking to challenge the dominant makers of weight-loss drugs Novo Nordisk and Eli Lilly. On top of the upfront purchase price of $2.7 billion, Carmot's equity holders will receive payments of up to $400 million if certain milestones are achieved, the Swiss drugmaker said in a statement on Monday. The takeover target's most promising drug candidate CT-388 belongs to a class known as a dual GLP-1/GIP receptor agonist, the same as Lilly's M...
(Bloomberg) -- Roche Holding AG agreed to pay as much as $3.1 billion for Carmot Therapeutics Inc., a developer of the new type of weight-loss treatments that’s sparked a pharma industry gold rush.Most Read from BloombergHow Suspects Laundered Billions in Singapore for YearsBonds Retreat as Doubts Over Rate Cuts Creep In: Markets WrapBitcoin Surges Past $42,000 as Crypto Rally Gathers SteamHere’s How to Invest in Gold as It Hits an All-Time HighAlaska Air Agrees to Buy Hawaiian in $1.9 Billion D
The voucher, which is transferable, allows a drug developer to expedite the review process of its product even if it does not fit requirements for a quick process. This would be the third priority voucher sale for bluebird after selling two for a combined $197 million over the past one year. The FDA's decision is expected by Dec. 20 and the bluebird therapy could potentially be the second for the rare disease.
/PRNewswire/ -- The "SARM1 Inhibitors Market by Target Indications, Type of Molecules, Drug Developers, Drug Candidates and Key Geographies: Industry Trends...